U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    61,747.42
    +2,454.45 (+4.14%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Emergent BioSolutions CEO Talks Coronavirus Vaccine Development

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Global life sciences company Emergent Biosolutions Inc (NYSE: EBS) CEO Bob Kramer said Thursday that his company's partnership with Novavax, Inc. (NASDAQ: NVAX) could result in the creation of a therapy that poses a "fairly low risk."

Emergent Has Past Experience With Anthrax, Botulism

Emergent is using its own platform to help Novavax with the creation of a coronavirus vaccine, Kramer said during a guest appearance on CNBC's "Squawk Box" segment Thursday morning. 

Emergent's products have been used in therapies to protect against anthrax and botulism, the CEO said, adding there is a "high probability" that a patient-ready vaccine could be in use "later this summer.

"We have been doing this for 22 years as a business, in fact that is all we do — focus on public health threats," he said.

Emergent's 'Decades Of Experience' 

Emergent is looking at alternative options for patients to obtain a vaccine prior to the summer months, Kramer said. 

The encouraging takeaway is that any product will have the company's "decades of experience" and management behind it, giving the CEO a high degree of confidence, he said. 

No 'Immediate Help' For Coronavirus 

Kramer said there is the possibility of working with multiple regulatory bodies to make a vaccine available earlier through an emergency use authorization or a compassionate use exception.

Outside of BioSolutions and Novavax, Kramer said therapeutic options from other companies can be made available in a "similar timeline," but there isn't much to expect in terms of "immediate help."

Related Links:

The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Teladoc, Ping Identity, Emergent Biosolutions: Portfolio Manager Shares Stock Picks After Monday's Carnage

 

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.